Scientists discover and test new class of pain relieversJune 01, 2016
DURHAM, N.C. -- A research team at Duke University has discovered a potential new class of small-molecule drugs that simultaneously block two sought-after targets in the treatment of pain.
These proof-of-concept experiments, published June 1 in Scientific Reports, could lead to the development of a new drug to treat conditions including skin irritation and itching, headaches, jaw pain, and abdominal pain stemming from the pancreas and colon.
More than 100 million people suffer from chronic pain in the United States, according to a report from the Institute of Medicine, and new medicines are badly needed.
"We are very pleased with what is a first chapter in a highly promising story," said Wolfgang Liedtke, M.D., Ph.D., a professor of neurology, anesthesiology and neurobiology at Duke University School of Medicine, who treats patients with head and face pain and other sensory disorders. "We hope to be able to develop these compounds for clinical use in humans or animals."
In the new study, the researchers initially aimed to develop more effective blockers of TRPV4, a molecule their previous research had shown transmits skin irritation elicited by sunburn, and painful sensations coming from the head and face. Liedtke and his Duke collaborator Farshid Guilak used a prototype TRPV4 blocker in a 2009 study and then set out to develop more potent versions.
Compared to the prototype, one of the new candidate drugs, called "16-8," worked 10 times more effectively in cells with active TRPV4 that are key for the development of osteoarthritis. It also worked well in another cell type involved in nerve cell injury, stroke and epilepsy.
But to their surprise, when assessing the specificity of 16-8, the scientists discovered that it also blocked TRPA1, which is a promising target in pain and itch research.
"As a physician, I soon realized the enormous potential that these compounds might have, given how beneficial dual-target molecules can be in clinical medicine," Liedtke said.
Both TRPV4 and TRPA1 are members of the family of TRP ion channels, which function in sensory nerve cells to directly sense painful stimuli. Other research groups are now targeting these channels in clinical trials for pain relief.
In this study, the drug 16-8 also quelled pain in living animals, including abdominal aches in mice with pancreas inflammation. So-called pancreatitis is extremely painful and difficult to treat, and new cases are on the rise globally, said study co-author Rodger Liddle, M.D., of the Duke University School of Medicine and a member of the Duke Institute for Brain Sciences.
Liedtke sees potential for the 16-8 drug to treat osteoarthritis and other types of joint pain as well as head, face and jaw pain. In general, it might also treat aches radiating from internal organs or resulting from nerve cell injury.
The group's preclinical work will focus on understanding the compound's potential use in these conditions as well as learning more about how it works. They also hope to explore topical applications to mucous membranes, which are present throughout the body and skin.
The study was supported by the National Institutes of Health (DE018549, AR48182, AR48182-S1, AR48852, AG15768, AR50245, AG46927, DK064213, DK091946, DK098796, F33DE024668, K12DE022793, K12CA100639, the U.S. Department of Defense (W81XWH-13-1-0299), the U.S. Department of Veterans Affairs, the National Science Foundation (1445792), the Arthritis Foundation, and the Harrington Discovery Institute Scholar-Innovator Award. Duke's Office of Licensing and Ventures is pursuing patent applications on this work.
CITATION: " Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain," Patrick Kanju, Yong Chen, Whasil Lee, Michele Yeo, Suk Hee Lee, Joelle Romac, Rafiq Shahid, Ping Fan, David M. Gooden, Sidney A. Simon, Ivan Spasojevic, Robert A. Mook, Rodger A. Liddle, Farshid Guilak and Wolfgang B. Liedtke. Scientific Reports, June 1, 2016. DOI: 10.1038/srep26894
Related Pain Relievers Current Events and Pain Relievers News Articles
Standardizing care improves outcomes for infants born with neonatal abstinence syndrome
Standardizing hospital care policies across institutions for infants diagnosed with drug withdrawal symptoms at birth reduces their length of treatment and hospitalization, according to new collaborative research led by Vermont Oxford Network, Vanderbilt and the University of Michigan Health System.
Penn researchers show rising opioid prescriptions following low-risk surgeries
Physicians are prescribing more opioid painkillers than ever before to patients undergoing common surgeries, according to new research from the department of Anesthesiology and Critical Care at the Perelman School of Medicine at the University of Pennsylvania.
Many use prescription painkillers, most see abuse as major health concern
More than one in four Americans has taken prescription painkillers in the past year, even as a majority say that abuse of these medications is a very serious public health concern, according to new Johns Hopkins Bloomberg School of Public Health research.
Risk profiling is key to managing pain in era of opioid abuse
Patients undergoing rehabilitation for physical injuries and their physicians can better understand who is most at risk of abusing opioids by reviewing their family history, lifestyle and environment for critical cues about susceptibility to addiction, according to physical medicine and rehabilitation experts.
Babies with drug withdrawal syndrome more likely to be readmitted
Infants diagnosed with drug withdrawal symptoms at birth, also known as neonatal abstinence syndrome (NAS), are nearly two and a half times as likely to be readmitted to the hospital in the first month after being discharged compared with full-term infants born without complications, according to new Vanderbilt research released today in the journal Hospital Pediatrics.
Patients prefer relief from lower back pain over improved mobility
A new study out today in the journal Neurology examines the question of quality of life for individuals with a common form of lower back pain called lumbar spinal stenosis.
Stanford researchers genetically engineer yeast to produce opioids
For thousands of years, people have used yeast to ferment wine, brew beer and leaven bread.
Model could help counteract poisoning from popular painkiller
New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines.
Seniors don't bounce back fast from car crashes
Many seniors injured in motor vehicle crashes remain in pain for months afterwards, which negatively affects their quality of life, including the ability to live independently.
Emergency department opioid prescribing
The Emergency Department (ED) is at the convergence of the opioid epidemic as emergency physicians (EPs) routinely care for patients with adverse effects from opioids, including overdoses and those battling addiction, as well as treating patients that benefit from opioid use.
More Pain Relievers Current Events and Pain Relievers News Articles